Taiko Pharmaceutical Co Ltd (4574)

Currency in JPY
283.0
-1.0(-0.35%)
Closed·

4574 Financial Summary

Key Ratios

P/E Ratio25.1
Price/Book2.26
Debt / Equity20.39%
Return on Equity9.32%
Dividend Yield0.00%
EBITDA886.00M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2016
31/03
2017
31/03
2018
31/03
2019
31/03
2020
31/03
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
* In Millions of JPY (except for per share items)

Earnings

Latest Release
May 09, 2025
EPS / Forecast
5.83 / --
Revenue / Forecast
1.15B / 1.68B
EPS Revisions
Last 90 days

FAQ

What were Taiko Pharmaceutical's earnings for the latest quarter?

The Taiko Pharmaceutical EPS (TTM) is 14.30. Taiko Pharmaceutical reported sales of 1,150.00, net income of 292.00, and EPS of 5.83 for the latest quarter.

What was Taiko Pharmaceutical's net income for the latest quarter?

Taiko Pharmaceutical's net income for the latest quarter was 292.00.

How did Taiko Pharmaceutical's performance compare year-over-year in the latest quarter?

The company's revenue moved from 1,713.00 in the previous quarter to 1,150.00 in the latest quarter, and net income moved from 184.00 to 292.00 compared to the previous quarter.

What is Taiko Pharmaceutical's net profit margin on a TTM basis?

Taiko Pharmaceutical's trailing twelve months (TTM) net profit margin is 14.27%.

How does Taiko Pharmaceutical's debt to equity ratio compare to industry standards?

Taiko Pharmaceutical's total debt-to-equity ratio is 20.39%.

What is Taiko Pharmaceutical's return on investment on a TTM basis?

Taiko Pharmaceutical's trailing twelve months (TTM) return on investment (ROI) is 9.32%.

What were Taiko Pharmaceutical's total assets and liabilities in the latest quarter?

As of the latest quarter, Taiko Pharmaceutical reported total assets of 12,161.00 million and total liabilities of 2,460.00 million.

How has Taiko Pharmaceutical's total revenue grown this year?

Taiko Pharmaceutical's total revenue was 1,713.00 in the previous quarter and 1,150.00 in the latest quarter.

What is Taiko Pharmaceutical's gross margin on a TTM basis?

Taiko Pharmaceutical's trailing twelve months (TTM) gross margin is 58.47%.

What was Taiko Pharmaceutical's revenue per share for the latest quarter?

Taiko Pharmaceutical's revenue per share for the latest quarter was 1,857.94.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.